Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Pfizer Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income attributable to Pfizer Inc. common shareholders1 (in millions) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
An analysis of the provided financial data over the multiple periods reveals several notable trends and fluctuations in share price, earnings per share (EPS), and the price-to-earnings (P/E) ratio.
- Share Price
- The share price experienced considerable volatility over the period examined. Starting at $26.26, it decreased notably to a low of $12.31 by early 2009. Following this trough, the price demonstrated a recovery phase, increasing steadily to peak near $45.96 in early 2022. However, the final two years saw a reversal with prices declining to $26.10 by early 2025, representing a substantial drop from the peak but comparable to the initial value in 2006.
- Earnings Per Share (EPS)
- EPS showed significant inconsistency throughout the periods. It surged early on to $2.73 in 2007, then fluctuated with a low around $1.03 in 2011, before climbing again to a high of $5.58 in 2023. Nonetheless, EPS plunged sharply to $0.38 in 2024 before partially rebounding to $1.42 in 2025. Such variability suggests episodic changes in profitability or one-time effects impacting earnings.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio mirrored the volatility in stock price and EPS, oscillating between single-digit lows and elevated values. Early periods saw a decline from 23.92 to 9.18, followed by fluctuations around the teens and twenties. The ratio spiked sharply to 73.42 in 2024, coinciding with the significant EPS decline, signaling a possible overvaluation or market uncertainty, before normalizing to 18.42 in 2025.
Overall, the data reflect a cycle of decline and recovery in share price and earnings over nearly two decades, with significant variability in profitability and valuation multiples. The sharp EPS decline and corresponding P/E surge in the penultimate period indicate an unusual event affecting earnings and investor perceptions, followed by partial recovery. These patterns emphasize the importance of contextual factors driving financial performance and market valuation during the timeframe analyzed.
Comparison to Competitors
Pfizer Inc., P/E, long-term trends, comparison to competitors
| Pfizer Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | ||||||||||||
| Feb 22, 2024 | ||||||||||||
| Feb 23, 2023 | ||||||||||||
| Feb 24, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 27, 2020 | ||||||||||||
| Feb 28, 2019 | ||||||||||||
| Feb 22, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 29, 2016 | ||||||||||||
| Feb 27, 2015 | ||||||||||||
| Feb 28, 2014 | ||||||||||||
| Feb 28, 2013 | ||||||||||||
| Feb 28, 2012 | ||||||||||||
| Feb 28, 2011 | ||||||||||||
| Feb 26, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 29, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Pfizer Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Pfizer Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 27, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 27, 2020 | ||
| Feb 28, 2019 | ||
| Feb 22, 2018 | ||
| Feb 23, 2017 | ||
| Feb 29, 2016 | ||
| Feb 27, 2015 | ||
| Feb 28, 2014 | ||
| Feb 28, 2013 | ||
| Feb 28, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Pfizer Inc., P/E, long-term trends, comparison to industry (health care)
| Pfizer Inc. | Health Care | |
|---|---|---|
| Feb 27, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 27, 2020 | ||
| Feb 28, 2019 | ||
| Feb 22, 2018 | ||
| Feb 23, 2017 | ||
| Feb 29, 2016 | ||
| Feb 27, 2015 | ||
| Feb 28, 2014 | ||
| Feb 28, 2013 | ||
| Feb 28, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).